Figure 1.
Study design and Kaplan–Meier curves in patients with mRCC. A, Blood samples (24 mL) were collected before nivolumab (baseline, T0) and after 1 (T1), 3 (T3), 6 (T6), and 12 (T12) months of treatment. Clinical assessment every 3 months. B, Study enrollment flow chart. C, Kaplan–Meier curve for PFS and overall survival (OS) in 57 nivolumab-treated patients with mRCC.